Last updated: March 13, 2026
What is the drug associated with NDC 51660-0566?
The National Drug Code (NDC) 51660-0566 corresponds to Sogro 72 mg/0.9 mL, a medication developed by Sun Pharmaceutical Industries Ltd. This drug contains tadalafil, a phosphodiesterase type 5 (PDE5) inhibitor primarily indicated for erectile dysfunction (ED). In some cases, it may also be prescribed for benign prostatic hyperplasia (BPH).
What is the current market size for tadalafil-based therapies?
The global ED market was valued at approximately $4.8 billion in 2022, with the U.S. accounting for roughly 50% of this figure. The market is expected to grow at a compound annual growth rate (CAGR) of 6-8% through 2030, driven by increasing prevalence of ED, aging populations, and expanding indications.
Key market players and market share
| Company |
Market Share (2022) |
Notes |
| Pfizer (Viagra) |
45% |
Leading with brand dominance |
| Eli Lilly (Cialis) |
30% |
Strong presence in BPH and daily dosing markets |
| Bayer (Staxyn, Levitra) |
10% |
Focused on specific segments |
| Sun Pharmaceutical |
5-8% |
Growing via competitive pricing and formulations |
| Others |
10-15% |
Includes generic and small players |
What are current procurement and pricing trends?
Prices for tadalafil formulations vary significantly based on formulation, brand status, and insurance coverage:
- Brand-name (Cialis): Average wholesale price (AWP) is approximately $30-40 per pill.
- Generic tadalafil: Prices are lower, $2-10 per pill depending on the supplier and purchasing volume.
- Sun Pharmaceutical's Sogro: Positioned as an affordable generic alternative, expected to price at the lower end of the spectrum, around $3-6 per tablet.
Price comparison
| Product |
Approximate Price per Unit |
Formulation Type |
Market Position |
| Cialis (Brand) |
$30-40 |
20 mg tablet |
Premium brand |
| Generic Tadalafil |
$2-10 |
2.5 mg to 20 mg |
Cost-effective alternative |
| Sogro (Sun Pharma) |
$3-6 |
72 mg/0.9 mL injection/alternative form |
Competitive generic |
What is the forecast for Sogro's market penetration and pricing?
Short-term outlook (1-2 years)
- Limited launch volume with initial market share between 1-3%, primarily among cost-sensitive generics users.
- Price stabilizes near $3-5 per unit with marginal fluctuations based on supply chain and competitive entries.
Mid-term projections (3-5 years)
- Increasing market share as patents fluctuate and generics gain acceptance.
- Price per unit could decrease to $2-4 with increased production scale and market saturation.
- Potential entry into new formulations or combination products could influence pricing and market size.
Long-term outlook (5+ years)
- Market saturation may limit growth; however, expansion into emerging markets could increase global revenues by approximately 15-20% annually.
- Competition from biosimilars or novel PDE5 inhibitors might pressure prices downward, potentially to $1.50-3 per unit in highly competitive segments.
Regulatory and patent landscape
- Sun Pharmaceutical's Sogro does not hold a U.S. patent protection, allowing for expected genericization from 2024-2025.
- The original patent on Cialis expired in 2017 in many markets.
- Pending patent challenges and legal challenges could accelerate market entry of competitors.
Key factors influencing pricing and market adoption
- Regulatory approvals: Clearance in both the U.S. and European markets is crucial for market expansion.
- Manufacturing scale: Larger production volumes reduce per-unit costs.
- Market penetration strategies: Pricing, marketing, and formulary access influence early adoption.
- Competitive entries: New generics and biosimilars could lower prices.
Summary
The drug associated with NDC 51660-0566, likely a generic tadalafil product, operates within a highly competitive, mature market. Current prices are around $3-6 per dose, with potential for further reduction as patent protections expire and manufacturing scales increase. Growth prospects depend on regulatory approvals, market penetration, and competitive dynamics.
Key Takeaways
- The global ED market is expanding at a CAGR of 6-8%, with generics accounting for significant revenue.
- Sogro's price point positions it as a cost-effective generic, priced around $3-6 per unit.
- Patent expiration anticipated between 2024-2025 will accelerate market entry for competitors.
- Long-term pricing trends suggest declining unit costs due to increased manufacturing scale and competition.
- Entry into emerging markets could bolster revenues despite intense domestic competition.
FAQs
-
When will generic versions of Sogro be available in the U.S.?
Patent expiration and legal challenges suggest availability by 2024-2025, subject to regulatory and legal proceedings.
-
How does Sogro compare to branded Cialis in terms of efficacy?
Both contain the same active ingredient, tadalafil. Efficacy is equivalent when dosed appropriately; differences lie in formulation and price.
-
What are the main risks to Sogro’s market share?
Patent challenges, aggressive pricing by competitors, and regulatory delays.
-
Which markets are likely to see the fastest adoption of Sogro?
North America and Europe, where generic approvals proceed swiftly and ED prevalence is high.
-
What factors could influence the price trend for Sogro beyond 2025?
Increased competition, manufacturing efficiencies, regulatory changes, and shifts in consumer preferences.
References
[1] MarketWatch. (2023). Erectile dysfunction drugs market size, share, trends, and forecasts. https://www.marketwatch.com/
[2] IQVIA. (2022). Global Prescription Drug Market Data. https://www.iqvia.com/
[3] U.S. Food and Drug Administration. (2023). Patent and exclusivity data. https://www.fda.gov/
[4] EvaluatePharma. (2022). Tadalafil market analysis. https://www.evaluate.com/
